Eli S. Williams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eli S. Williams has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Sohil H. Patel
Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, USA
2 shared publications - Alejandro A. Gru
Department of Dermatology, Division of Dermatopathology Columbia University Irving Medical Center/NewYork‐Presbyterian New York New York USA
1 shared publication - Allison Cruise
University of New Mexico USA
1 shared publication - Anna C. Dusenbery
Strata Oncology, Ann Arbor, Michigan
1 shared publication Ashley P. Craddock
Pathology
1 shared publicationChelsea Chambers
Department of Neurology, University of Virginia, Charlottesville, VA, USA
1 shared publication
Latest Publications
- Open Access
- 4 July 2025
- Published by Springer Nature in Medical Science Educator
- Vol. 35 (5) , 2621-2623
Artificial Intelligence–Powered Answers to Questions in Genomic Medicine
We asked first-year medical students to critique ChatGPT-generated responses to questions in genomic medicine. Students compared AI outputs to biomedical literature, highlighting AI’s strengths and limitations. The exercise fosters critical thinking about AI in healthcare, in alignment with recommendations for integrating AI into medical education.
- 4 July 2025
- Published by Springer Nature in Medical Science Educator
- Vol. 35 (5) , 2621-2623
Open AccessArtificial Intelligence–Powered Answers to Questions in Genomic Medicine
We asked first-year medical students to critique ChatGPT-generated responses to questions in genomic medicine. Students compared AI outputs to biomedical literature, highlighting AI’s strengths and limitations. The exercise fosters critical thinking about AI in healthcare, in alignment with recommendations for integrating AI into medical education.
- 6 June 2024
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 45 (7) , E22
A Note of Caution Regarding Single-Arm 1p or 19q Deletion in IDH -Mutant Gliomas
- 6 June 2024
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 45 (7) , E22
A Note of Caution Regarding Single-Arm 1p or 19q Deletion in IDH -Mutant Gliomas
- 1 June 2023
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 69 (6) , 665-666
Proximity Sequencing Enables Measurement of Protein Complexes in Single Cells
- 1 June 2023
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 69 (6) , 665-666
Proximity Sequencing Enables Measurement of Protein Complexes in Single Cells
- 24 May 2023
- Published by Springer Nature
- p. 1275-1311
Neuroimaging of Brain Tumors in the Era of Radiogenomics
- 24 May 2023
- Published by Springer Nature
- p. 1275-1311
Neuroimaging of Brain Tumors in the Era of Radiogenomics
- 24 January 2022
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 46 (7) , 956-962
Use of Ultrasensitive RNA In Situ Hybridization for Determining Clonality in Cutaneous B-Cell Lymphomas and Lymphoid Hyperplasia Decreases Subsequent Use of Molecular Testing and Is Cost-effective
Primary cutaneous B-cell lymphomas (PCBCLs) are diagnostically challenging entities due to significant overlap in clinical and morphologic features with reactive lymphoid proliferations. Traditional methods for evaluating clonality such as immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) are limited by low sensitivity, which leads to additional costly and time-consuming molecular clonality assays. More recent technology has introduced ultrasensitive bright-field RNA in situ hybridization (BRISH) to the field, which can detect single molecules of light-chain mRNA. The current study evaluated 274 cases of PCBCL in addition to atypical and reactive lymphoid infiltrates, with CISH or BRISH performed on 180 (65.7%). CISH was performed on 105 (58.3%), and BRISH was performed on 75 (41.7%). Significantly fewer immunoglobulin heavy-chain (IGH) rearrangement studies were performed on cases that were evaluated with BRISH as compared with CISH (P=0.02). Subgroup analysis demonstrated that cases with restriction by BRISH were significantly less likely to have subsequent IGH studies performed (P=0.01). The expected costs of cases using CISH versus BRISH were $1053.89 versus $810.32 to the patient and $245.63 versus $225.23 to the laboratory. The use of ultrasensitive BRISH to evaluate clonality in PCBCL reduced the use of IGH rearrangement studies when compared with CISH. In particular, cases with light-chain restriction by BRISH did not result in confirmatory molecular testing. Despite slightly higher costs to the laboratory to perform BRISH, routine use of this methodology can result in cost savings to both the patient and laboratory by decreasing the use of expensive molecular methods.
- 24 January 2022
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 46 (7) , 956-962
Use of Ultrasensitive RNA In Situ Hybridization for Determining Clonality in Cutaneous B-Cell Lymphomas and Lymphoid Hyperplasia Decreases Subsequent Use of Molecular Testing and Is Cost-effective
Primary cutaneous B-cell lymphomas (PCBCLs) are diagnostically challenging entities due to significant overlap in clinical and morphologic features with reactive lymphoid proliferations. Traditional methods for evaluating clonality such as immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) are limited by low sensitivity, which leads to additional costly and time-consuming molecular clonality assays. More recent technology has introduced ultrasensitive bright-field RNA in situ hybridization (BRISH) to the field, which can detect single molecules of light-chain mRNA. The current study evaluated 274 cases of PCBCL in addition to atypical and reactive lymphoid infiltrates, with CISH or BRISH performed on 180 (65.7%). CISH was performed on 105 (58.3%), and BRISH was performed on 75 (41.7%). Significantly fewer immunoglobulin heavy-chain (IGH) rearrangement studies were performed on cases that were evaluated with BRISH as compared with CISH (P=0.02). Subgroup analysis demonstrated that cases with restriction by BRISH were significantly less likely to have subsequent IGH studies performed (P=0.01). The expected costs of cases using CISH versus BRISH were $1053.89 versus $810.32 to the patient and $245.63 versus $225.23 to the laboratory. The use of ultrasensitive BRISH to evaluate clonality in PCBCL reduced the use of IGH rearrangement studies when compared with CISH. In particular, cases with light-chain restriction by BRISH did not result in confirmatory molecular testing. Despite slightly higher costs to the laboratory to perform BRISH, routine use of this methodology can result in cost savings to both the patient and laboratory by decreasing the use of expensive molecular methods.
- 1 August 2020
- Published by Elsevier in Human Pathology
- Vol. 102, 88-93
Chromosomal microarray analysis of benign mesenchymal tumors with RB1 deletion
- 1 August 2020
- Published by Elsevier in Human Pathology
- Vol. 102, 88-93
Chromosomal microarray analysis of benign mesenchymal tumors with RB1 deletion
- Open Access
- 25 March 2018
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 6 (3) , 457-462
Phase determination using chromosomal microarray and fluorescence in situ hybridization in a patient with early onset Parkinson disease and two deletions in PRKN
Background: Mutations in the parkin gene (PRKN) are the most commonly identified genetic factors in early onset Parkinson disease (EOPD), with biallelic mutations, resulting in a clinical phenotype. However, normal variation is also common in PRKN, particularly in the form of copy number variation (CNV), challenging interpretation of genetic testing results. Here we report a case of a 29‐year‐old male with EOPD and two deletions in PRKN detected by chromosomal microarray (CMA).Methods: The proband was clinically examined by a neurologist for postural instability with frequent falls, bradykinesia, gait freezing with festination, and hypophonia. Chromosomal microarray analysis (CMA) was performed on the proband and his parents using the Affymetrix CytoScan HD microarray. Subsequent fluorescence in situ hybridization (FISH) was performed on the proband and both parents.Results: Chromosomal microarray detected the presence of two deletions of PRKN in the proband. Parental CMA analysis was performed to determine the clinical significance of this finding, as well as to demonstrate phase of these deletions. Parental CMA revealed that one deletion was paternally inherited and one deletion was de novo. A custom FISH approach was then successfully used to phase the deletions.Conclusion: Chromosomal microarray and fluorescence in situ hybridization analysis of this trio identified two deletions in PRKN occurring in trans, providing a genetic etiology for the clinical diagnosis of EOPD. The determination of inheritance and phase of the deletions was critical to the proper interpretation of these results. These findings highlight the utility of CMA in the detection of clinically relevant CNVs in cases of EOPD, and also serve to emphasize the importance of follow‐up FISH and parental testing.
- 25 March 2018
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 6 (3) , 457-462
Open AccessPhase determination using chromosomal microarray and fluorescence in situ hybridization in a patient with early onset Parkinson disease and two deletions in PRKN
Background: Mutations in the parkin gene (PRKN) are the most commonly identified genetic factors in early onset Parkinson disease (EOPD), with biallelic mutations, resulting in a clinical phenotype. However, normal variation is also common in PRKN, particularly in the form of copy number variation (CNV), challenging interpretation of genetic testing results. Here we report a case of a 29‐year‐old male with EOPD and two deletions in PRKN detected by chromosomal microarray (CMA).Methods: The proband was clinically examined by a neurologist for postural instability with frequent falls, bradykinesia, gait freezing with festination, and hypophonia. Chromosomal microarray analysis (CMA) was performed on the proband and his parents using the Affymetrix CytoScan HD microarray. Subsequent fluorescence in situ hybridization (FISH) was performed on the proband and both parents.Results: Chromosomal microarray detected the presence of two deletions of PRKN in the proband. Parental CMA analysis was performed to determine the clinical significance of this finding, as well as to demonstrate phase of these deletions. Parental CMA revealed that one deletion was paternally inherited and one deletion was de novo. A custom FISH approach was then successfully used to phase the deletions.Conclusion: Chromosomal microarray and fluorescence in situ hybridization analysis of this trio identified two deletions in PRKN occurring in trans, providing a genetic etiology for the clinical diagnosis of EOPD. The determination of inheritance and phase of the deletions was critical to the proper interpretation of these results. These findings highlight the utility of CMA in the detection of clinically relevant CNVs in cases of EOPD, and also serve to emphasize the importance of follow‐up FISH and parental testing.